Top Ranked Momentum Stocks To Buy For August 2nd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 2nd:

Agnico Eagle Mines Limited (AEM): This explorer and developer of mineral properties has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 47.1% over the last 60 days.

Agnico Eagle Mines Limited Price and Consensus

Agnico Eagle's shares gained 5.8% over the last one month compared to S&P 500’s fall of -1.8%. The company possesses a Momentum Score of A.

Agnico Eagle Mines Limited Price

Biogen Inc (NASDAQ:BIIB). (BIIB): This developer of innovative therapies for treating serious neurological and neurodegenerative diseases has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.1% over the last 60 days.

Biogen Inc. Price and Consensus

Biogen's shares gained 2.1% over the last one month. The company possesses a Momentum Score of A.

Biogen Inc. Price

American International Group (NYSE:AIG), Inc. (AIG): This provider of property-casualty, life and retirement, and general insurance services has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.6% over the last 60 days.

American International Group, Inc. Price and Consensus

American International’s shares gained 0.8% over the last one month. The company possesses a Momentum Score of A.

American International Group, Inc. Price

Ally Financial Inc. (ALLY): This digital financial-services company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.8% over the last 60 days.

Ally Financial Inc. Price and Consensus

Ally’s shares gained 2.5% over the last one month. The company possesses a Momentum Score of B.

Ally Financial Inc. Price

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>